Radiopharm Theranostics Limited (RADX) Earnings History
Net Loss4 years of earnings data (2021–2024) · Currently unprofitable on a TTM basis
Loading earnings history...
Radiopharm Theranostics Limited (RADX) Earnings Overview
As of July 8, 2026, Radiopharm Theranostics Limited (RADX) reported trailing twelve-month net income of -$38M, reflecting +85.3% year-over-year growth. The company earned $-5.28 per diluted share over the past four quarters, with a net profit margin of -1055.3%.
Looking at the long-term picture, RADX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$30M in fiscal 2021.
Radiopharm Theranostics Limited is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RNW ($10.40B net income, 7.9% margin), RNAZ (-$40M net income), LNTH ($279M net income, 15.2% margin), RADX has room to improve margins relative to the peer group. Compare RADX vs RNW →
RADX Earnings vs Peers
Earnings metrics vs comparable public companies
RADX Historical Earnings Data (2021–2024)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$38M | +20.0% | -$38M | $-5.28 | -1055.3% | -1050.6% |
| 2023 | -$48M | -38.5% | -$37M | $-36.00 | -16024.3% | -12238.4% |
| 2022 | -$35M | -14.1% | -$35M | $-33.00 | -11838.6% | -11803.3% |
| 2021 | -$30M | - | -$20M | $-29.76 | -343550.9% | -225527.7% |
Download Data
Export RADX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RADX — Frequently Asked Questions
Quick answers to the most common questions about buying RADX stock.
What is RADX earnings per share (EPS)?
RADX trailing twelve-month (TTM) diluted EPS is $-5.28, reflecting +85.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2021 to 2024 is available in the table on this page.
What is Radiopharm Theranostics Limited's net income?
Radiopharm Theranostics Limited (RADX) trailing twelve-month net income is $-38M as of 2024. Earnings grew +85.3% year-over-year.
Is RADX profitable?
RADX is not currently profitable on a TTM basis, reporting a net loss of $-38M. Net margin is -1055.3%. Investors should monitor for a return to profitability.
What is RADX's earnings growth rate?
RADX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2021 to 2024.
What are RADX's profit margins?
Radiopharm Theranostics Limited net profit margin is -1055.3%, operating margin is -1050.6%, and gross margin is +1.1%. Below-average margins reflect competitive or cost pressures. Return on Equity is -109.2%.
Is RADX growing earnings?
Yes, RADX earnings are accelerating — EPS growth of +85.3% exceeds the 5-year CAGR of N/A. TTM net income reached $-38M. Earnings momentum is strengthening.
What was RADX's best earnings year?
Radiopharm Theranostics Limited's highest annual net income on record is $-30M, achieved in fiscal year 2021. Earnings history on this page spans 2021 to 2024 and includes all annual and quarterly figures.